Investigating Elacestrant for treating breast cancer that has spread to bones
Elacestrant in breast cancer bone metastases
This study is looking at how a new treatment called Elacestrant works for advanced breast cancer that has spread to the bones, and it’s for patients who might want to try a new way to fight this tough condition.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-11129606 on NIH RePORTER |
What this research studies
This research focuses on the use of Elacestrant, a new therapy approved for certain types of advanced breast cancer, particularly those that have spread to the bones. The study aims to understand how Elacestrant works differently in the bone environment compared to cancer cells, potentially offering a more effective treatment option. By using various laboratory models, the research will explore the effectiveness of Elacestrant in combating breast cancer metastasis to bones, which is a challenging condition to treat. Patients may have the opportunity to participate in trials that evaluate this innovative approach to therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with estrogen receptor-positive breast cancer that has spread to the bones, particularly those who have not responded to existing treatments.
Not a fit: Patients with breast cancer that is not estrogen receptor-positive or those whose cancer has not metastasized to the bones may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with breast cancer that has metastasized to the bones, potentially improving outcomes and quality of life.
How similar studies have performed: While Elacestrant has been approved for a subset of patients, its specific application in treating bone metastases is still being explored, indicating a novel approach in this area.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Zboril, Emily Kate — Virginia Commonwealth University
- Study coordinator: Zboril, Emily Kate
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.